Cargando…
Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation
BACKGROUND: Whether the early use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have cardioprotective effects following acute myocardial infarction is unknown. Thus, we aimed to evaluate the association between the early initiation of SGLT2 inhibitors and cardiac event rates in patients with...
Autores principales: | Kwon, Osung, Myong, Jun‐Pyo, Lee, Yunhee, Choi, Yeon‐Jik, Yi, Jeong Eun, Seo, Suk Min, Jang, Sung‐Won, Kim, Pum Joon, Lee, Jung‐Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382092/ https://www.ncbi.nlm.nih.gov/pubmed/37421263 http://dx.doi.org/10.1161/JAHA.122.027824 |
Ejemplares similares
-
Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
por: Gilbert, Richard E., et al.
Publicado: (2019) -
Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users
por: Zhou, Jiandong, et al.
Publicado: (2022) -
Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction
por: Connelly, Kim A., et al.
Publicado: (2018) -
So Much to Say on the Best of What's Around Regarding Sodium‐Glucose Cotransporter‐2 Inhibitors in Acute Myocardial Infarction
por: Nunes, Jairo T., et al.
Publicado: (2023) -
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
por: Seo, Ji A
Publicado: (2019)